Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 483

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 483
---
emnification Agreements Kadimastem has entered into employment agreements with each of its executive officers, which set forth the terms and conditions of each executive’s employment, including base salary, performance -basedvariable pay compensation and benefit plan participation. Under these agreements, each of its executive officers is employed for a specified time period. Kadimastem and/or its subsidiaries may terminate employment without notice, at any time, for certain acts of the executive officer, such as serious, repeated or continuing breach of internal policies or guidelines on conduct, any act or conduct which would bring the officer or Kadimastem into disrepute, any serious misconduct, unreasonable absenteeism or willful disobedience of Kadimastem lawful orders, willful refusal to perform all or any duties, insubordination, breach of Kadimastem secrecy, or violation of the laws and regulations of Israel. Kadimastem and/or its subsidiaries may also terminate an executive officer’s employment with advanced written notice. The length of such notice period is set out in each contract in accordance with the applicable law of Israel. Without delivering an advanced written notice, Kadimastem may also terminate an executive officer’s employment by paying to such officer salary in lieu of notice for the remainder of the relevant notice period. The executive officer may resign at any time by delivering to Kadimastem an advanced written notice. There are no severance provisions contained in these agreements. Kadimastem has entered into indemnification agreements with each of its directors and executive officers. Under these agreements, and subject to the terms thereof being in compliance with the Israeli Employment Act, Kadimastem has agreed to indemnify our directors and executive officers against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being a director or officer of Kadimastem. The following table presents in the aggregate all compensation Kadimastem paid to all of its directors and executive officers from January1, 2023, through December31, 2023. The table does not include any amounts Kadimastem paid to reimburse any of such persons for costs incurred in providing us with services during this period. All amounts reported in the tables below reflect Kadimastem’s cost. Amounts paid in NIS are translated into U.S. dollars at the rate of NIS 3.689 = U.S. $1.00, based on the average representative rate of exchange between the NIS and the U.S. dollar as reported by the Bank of Israel during